Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Receivables (2017 - 2019)

Historic Receivables for Arcus Biosciences (RCUS) over the last 3 years, with Q2 2019 value amounting to $62000.0.

  • Arcus Biosciences' Receivables fell 8422.39% to $62000.0 in Q2 2019 from the same period last year, while for Jun 2019 it was $62000.0, marking a year-over-year decrease of 8422.39%. This contributed to the annual value of $183000.0 for FY2018, which is 26600.0% up from last year.
  • Per Arcus Biosciences' latest filing, its Receivables stood at $62000.0 for Q2 2019, which was down 8422.39% from $183000.0 recorded in Q4 2018.
  • Arcus Biosciences' 5-year Receivables high stood at $5.1 million for Q3 2018, and its period low was $50000.0 during Q4 2017.
  • For the 3-year period, Arcus Biosciences' Receivables averaged around $982666.7, with its median value being $145500.0 (2018).
  • Its Receivables has fluctuated over the past 5 years, first surged by 26600.0% in 2018, then crashed by 8422.39% in 2019.
  • Arcus Biosciences' Receivables (Quarter) stood at $50000.0 in 2017, then skyrocketed by 266.0% to $183000.0 in 2018, then plummeted by 66.12% to $62000.0 in 2019.
  • Its Receivables stands at $62000.0 for Q2 2019, versus $183000.0 for Q4 2018 and $5.1 million for Q3 2018.